Scarica l'app Stockscreener
27.76
0.43%
0.12
Dopo l'orario di chiusura:
27.76
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Alkermes Plc Borsa (ALKS) Ultime notizie
Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance
Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn
Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe
Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com
Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace
Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN
Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - Sahm
Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat
Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat
Why analysts are rating Alkermes (ALKS) a buy - MSN
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks
Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN
(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits
Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat
Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (ALKS) CEO granted 88,843 restricted stock units in Form 4 - Stock Titan
TD Asset Management Inc Sells 91,772 Shares of Alkermes plc $ALKS - MarketBeat
2,034-share Rule 144 sale by Alkermes insider (NASDAQ: ALKS) - Stock Titan
ALKS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Celebrating LGBTQIA+ Mental Health Trailblazers - CSRwire
Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review
Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance
Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan
Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan
5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan
Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com
Alkermes Plc (ALKS) Stock Analysis: Exploring A 45% Potential Upside In Biopharma - DirectorsTalk Interviews
American Century Companies Inc. Purchases 740,248 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes Releases Third Annual Corporate Responsibility Report - CSRwire
ALKSAlkermes plc Reports Results for Fiscal 2012 and Provides Expectations for Fiscal 2013 - mx.advfn.com
Alkermes plc $ALKS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Alkermes (ALKS) VP exercises RSUs and withholds 808 shares for tax - Stock Titan
Alkermes (ALKS) CCO logs RSU exercise and tax share withholding - Stock Titan
Alkermes (ALKS) COO logs RSU share gain and tax-related share disposal - Stock Titan
Alkermes (ALKS) EVP Hopkinson converts 6,866 RSUs, withholds 3,049 shares for taxes - Stock Titan
Alkermes (ALKS) EVP Gaffin exercises RSUs, withholds 3,049 shares for tax - Stock Titan
Alkermes’ ALKS 2680 Narcolepsy Study Completion: What Investors Should Watch Next - TipRanks
Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright lowers Alkermes stock price target on revenue guidance By Investing.com - Investing.com Canada
4 Analysts Have This To Say About Alkermes - Benzinga
Wells Fargo Boosts Price Target for Alkermes (ALKS), Maintains O - GuruFocus
Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic - CSRwire
ALKS: RBC Capital Adjusts Price Target; Maintains Outperform Rat - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Alkermes (NASDAQ:ALKS) Stock Price - MarketBeat
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change - Zacks Investment Research
Alkermes Reveals CEO Succession Plan Following Richard Pops’ Retirement Announcement - Pharmaceutical Executive
RBC Lowers Price Target on Alkermes to $45 From $47, Keeps Outperform Rating - marketscreener.com
Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Alkermes stock price target on revenue guidance - Investing.com
Alkermes Plc earnings missed by $0.12, revenue topped estimates - Investing.com Australia
Decoding Alkermes PLC (ALKS): A Strategic SWOT Insight - GuruFocus
Alkermes CEO Richard Pops to retire after 35 years, Jackson named successor - Investing.com Nigeria
Alkermes plc 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ALKS) 2026-02-25 - Seeking Alpha
Alkermes FY 2025 presentation: transition year sets stage for growth By Investing.com - Investing.com Australia
Alkermes Earnings Call: Growth, LUMRIZE and New Risks - TipRanks
Does Alkermes’ Weaker 2025 Results and CEO Changeover Shift the Bull Case for ALKS? - Yahoo Finance
Alkermes (ALKS) CCO converts 6,407 RSUs, withholds 2,845 shares for tax - Stock Titan
Alkermes (NASDAQ: ALKS) COO exercises RSUs, shares withheld for tax - Stock Titan
[Form 4] Alkermes plc. Insider Trading Activity - Stock Titan
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
Alkermes (ALKS) Announces CEO Transition as Shares Dip - GuruFocus
Alkermes PLC (ALKS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Alkermes (ALKS) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is Alkermes (ALKS) Pricing In Its Neuroscience And Orexin Pipeline Potential? - simplywall.st
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):